By KCI, an Acelity Company
San Antonio, TX, – May 21, 2019 – KCI, an Acelity Company, announces that the Company has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for DERMATAC™ Drape, a proprietary silicone-acrylic hybrid drape that provides both clinical and operational benefits, as an accessory to certain of KCI’s Negative Pressure Wound Therapy (NPWT) Systems. Constructed with a precise combination of silicone and acrylic, DERMATAC™ Drape conforms to different anatomical locations, adapting to the body and providing a tight, highly effective seal for 48 to 72 hours, including uneven areas, for wound protection, creating the ideal balance for wound healing support.